Small Cap News Context

Blaize issues fractional Series B preferred to enable potential reverse stock split

Blaize declared a dividend of one one‑thousandth share of newly designated Series B Preferred for each outstanding common share (record date Oct. 26, 2026) intended to facilitate a possible reverse stock split. The Series B Preferred will vote with common stock only on any proposal to reclassify common into fewer shares (and adjournments), carries 1,000 votes per one‑one‑thousandth share (1,000,000 votes per full preferred share), and shares not present at the vote will be automatically redeemed; the board can also redeem outstanding Series B Preferred upon approval or at its discretion.

RUBI announces $8.5M registered direct: $9.44M senior convertibles + 25.9M warrants, 1st close ~Oct 19

Rubico entered a registered direct with one institutional investor to sell senior convertible notes with $9,444,444 face amount (10% OID) and attached warrants, receiving $8.5M gross proceeds at the expected first-tranche closing on or about Oct 19, 2026; the notes bear 8% cash interest (10% if paid in shares), convert at a Fixed Conversion Price of $0.3646, and include an alternate holder conversion tied to VWAP with a $0.10 floor. The warrants are immediately exercisable for 25,903,577 common shares at $0.3646 (5-year term) and the company will issue Commitment Shares equal to 5% of note face value at each tranche (1,295,179 expected at the first tranche); a second tranche (additional $5,555,556 principal for $5.0M gross) is available subject to conditions; Maxim Group is sole placement agent. Timing: The press release does not indicate dilution today. Earliest dilution: date unknown.

XCF CEO says Reno plant is ramping to commercial ops, reports Aug revenue and Sept sales; closes business combination

XCF Global (SAFX) CEO addressed recent share-price volatility and said the New Rise Reno facility is transitioning to commercial operations, reporting >$10M revenue in August, >$12M in gross product sales in September and ~85,000 gallons/day production by end-September; the company also closed its business combination with Southern Energy Renewables and DevvStream. Management says these milestones support a ramp toward the plant's 38–40M gallon/year nameplate capacity but notes the sales figures are non‑GAAP, profitability is not yet established, and the company flagged risks including Nasdaq compliance, lease and lender disputes, integration and financing challenges.

VCI Global (VCIG) pivots to AI infrastructure, launches VGAIN Compute; 1H2026 equity up but revenue plunges

VCI Global reported 1H2026 unaudited results and said it is shifting from capital markets/fintech to AI computing, token services and related infrastructure, launching VGAIN Compute and agreeing to acquire a 70% stake in an Indonesian carbon-asset platform (FCCI). Financially, total equity rose 19.2% to $114.7M, liabilities fell 17.7% to $17.03M and cash increased to $5.19M, but revenue dropped 86% to $2.56M and the company posted a $8.43M net loss after divesting non-core businesses. VGAIN Compute is live with a token-based model giving paid access to multiple LLMs (OpenAI GPT, Meta Llama, Kimi, Qwen); commercial traction, GPU capacity deployment and financing will determine whether the strategic pivot translates into recurring revenue.

LQR House (YHC) CEO Sean Dollinger steps down; Leo Chen named as company pivots to AI-enabled brokerage

LQR House (NASDAQ: YHC) said CEO Sean Dollinger stepped down effective Oct 16, 2026 and Leo Chen was named CEO as the company shifts strategy toward its New Zealand acquisition Fusion Five Continents Securities and a technology agreement with ByteDance to add AI compute for quantitative research. The company will transfer its online spirits business to a firm owned by outgoing CFO Kumar Abhishek and says Fusion Five will operate as an AI-enabled cross-border brokerage that can accept USDT deposits — a material change in business mix with potential regulatory and execution implications.

POAS files Form 20-F; FY26 revenue down, cash and equity improve

Phaos Technology (POAS) filed its Form 20-F for the fiscal year ended April 30, 2026, reporting revenue of S$132,077 versus S$167,707 in FY25 and saying delayed customer orders and non-recurring IPO/business-development costs weighed on FY26. Cash rose to S$762,234 from S$129,552, shareholders' equity turned to S$5.30M from a S$1.96M deficit, service revenue increased 59.3% to S$10,845, and the company expects revenue momentum in the six months ended October 2026 as delayed orders are captured.

TGL seeks authorization for 1-for-2 to 1-for-50 reverse split to regain Nasdaq $1 bid compliance

TGL filed SEC Form PRE 14A. Treasure Global Inc. filed a preliminary proxy (PRE 14A) to hold a virtual special meeting on November 5, 2026 asking shareholders to approve an amendment authorizing the board to effect a reverse stock split at any whole-number ratio between 1-for-2 and 1-for-50 to try to meet Nasdaq Listing Rule 5550(a)(2). The filing shows 3,484,484 shares outstanding as of the September 18, 2026 record date, the board recommends FOR the proposals, the board would have up to 12 months after approval to implement the split, fractional shares would be rounded up to whole shares, and authorized shares would remain at 600,000,000 (increasing authorized-but-unissued shares).

XCF (SAFX) closes all-stock deal with Southern Energy and DevvStream; updates 2027 outlook

XCF Global (SAFX) completed an all-stock business combination with Southern Energy Renewables and DevvStream, which are now wholly owned subsidiaries and whose former equity holders own ~20.0% and ~10.43% of XCF respectively, creating a vertically integrated platform combining HEFA-based fuel production, planned gasification feedstock pathways and internal environmental-asset monetization. XCF updated its 2027 outlook to $650–700M gross product sales, $120–130M net revenue and $70–75M EBITDA and disclosed 2030 targets (>$1.4B gross sales, >$400M net revenue, >$300M EBITDA), while warning these are forward-looking and subject to operational, financing, regulatory and facility-specific risks.

ZETA registers 287,711-share resale; will issue up to $1.25M of Class A over several quarters for services

ZETA filed SEC Form 424B5. Selling stockholders’ 287,711 Class A shares (from the Senso acquisition) are registered for resale and may be sold into the market from time to time, creating immediate resale overhang. Separately, Zeta will issue up to $1,250,000 of Class A common stock to a service provider over the next several fiscal quarters as payments become due, which will dilute existing holders when each issuance occurs. The number of shares issued for each payment will be calculated by dividing the dollar amount due by the 5‑day VWAP ending the trading day before each payment date (i.e., issuance price tied to 5‑day VWAP).

Actinium (ATNM) grants options and RSUs to new CFO and SVP Biz Dev

Actinium hired Matt David as CFO and Sean Maenpaa as SVP Business Development and granted inducement equity: David received a 10‑year option for 250,000 shares at $0.97 plus 250,000 RSUs and up to 75,000 milestone RSUs; Maenpaa received a 10‑year option for 40,000 shares at $1.06 plus 20,000 RSUs and 50,000 milestone RSUs. Options vest 28% after one year then in 2% monthly installments over the next 36 months; awards were granted outside the company’s 2019 Stock Plan as NYSE inducements, creating potential dilution if all awards vest/exercised while tying pay to retention and corporate milestones.

Xcel Brands files preliminary proxy for Dec 15, 2026 meeting; board seeks +650,000-share increase to equity plan

XELB filed SEC Form PRE 14A. Xcel Brands filed a preliminary Schedule 14A establishing its 2026 Annual Meeting for December 15, 2026 (record date Oct 19, 2026) where stockholders will vote to elect five directors, ratify Wolf & Company as auditors and approve an amendment to increase the 2021 Equity Incentive Plan from 1,150,000 to 1,800,000 shares (an additional 650,000 shares). The Board unanimously recommends votes "FOR" the director slate, auditor ratification and the plan increase. The company reports 6,908,839 shares outstanding as of the record date and only 58,688 shares remain available under the 2021 Plan pre-amendment, so the amendment would make up to 650,000 additional shares available if approved.

Alector prices 36.6M-share follow-on at $2.05; delivery ~Oct 19, 2026

ALEC filed SEC Form 424B5. New investors face immediate net tangible book value dilution: as-adjusted NTBV ~$0.41/share and dilution of approximately $1.64 per share; underwriting discount is $0.123/share. Company and insiders are subject to a 30-day lock-up from the prospectus date (Oct 16, 2026) restricting sales until about Nov 15, 2026, and an ATM Sales Agreement (up to $125M) remains available but is not being used until the lock-up expires.

NWTG takes option on Pole Canyon beryllium‑tungsten project, issues ~19.9% of shares

Newton Golf (NWTG) completed an option to acquire the Pole Canyon beryllium‑tungsten property in White Pine County, Nevada and issued shares equal to 19.9% of its outstanding common stock (estimated ≈1.13M shares) to gain exposure to U.S. critical minerals. The company says it does not plan to begin mining now and will pursue strategic agreements; a research update expects no near‑term revenue or operating income impact but narrowed FY:26 and FY:27 loss‑per‑share estimates, while noting the project’s historical resource numbers are unverified and the business remains cash‑flow negative.

GPUS says askROI to go public in Q2–Q3 2027; leadership shift planned

Hyperscale Data (GPUS) announced its askROI subsidiary is preparing to become a standalone public company via an RTO, IPO or SPAC, targeting closing in the second or third quarter of 2027. The company named Joseph Spaziano likely to become askROI CEO and Ryan Doucette president to create a dedicated management team and said the separation is intended to unlock independent valuation, but the transaction structure, timing and completion are not guaranteed.

Lexin (LX) gets Nasdaq notice for ADS price below $1, given until Apr 12, 2027 to regain compliance

Lexin (NASDAQ: LX) received a Nasdaq notice saying its ADSs closed below the $1.00 minimum bid price between Sept 1 and Oct 13, 2026 and it has 180 days (until April 12, 2027) to regain compliance by meeting or exceeding $1.00 for at least ten consecutive business days. The notice is procedural and ADSs continue to trade; the company is evaluating options to cure the deficiency (including an ADS-to-Class A share ratio adjustment) but warned there is no assurance it will regain compliance and delisting could follow if it fails to do so.

LASE names founder Dmitri Nikitin Executive Chairman and assumes CEO duties

Laser Photonics (LASE) appointed founder Dmitri Nikitin as Executive Chairman and principal executive officer with the authority and responsibilities of a CEO after Wayne Tupuola resigned for medical reasons; the company does not currently intend to appoint a separate CEO. Nikitin will prioritize expanding into higher-value defense and semiconductor markets, advancing the Laser Shield Anti-Drone (LSAD) platform, strengthening engineering and sales, and integrating prior acquisitions — he brings 35+ years of laser-technology experience and recent patent filings.

TDTH closed $23M primary raises (50M Class B shares) — immediate dilution

TDTH filed SEC Form 6-K. Trident closed $23.0M of primary financings by issuing 20,000,000 Class B shares at $0.40 (private placement closed Sep 8, 2026) and 30,000,000 Class B shares at $0.50 (registered direct closed Sep 29, 2026), creating 50,000,000 newly issued Class B shares and immediate dilution. The filing also discloses an $8.0M founder debt-to-equity conversion approved July 8, 2026 and a $2.0M share issuance in exchange for DIG common stock (initial closing July 17, 2026), both of which add further dilution/overhang. Timing: Shares were issued at closing on Sep 8, 2026; initial share dilution has already occurred.

NNOX: Preliminary Q3 revenue $4.3-4.4M; cash ~$26M, going-concern flagged

Nanox reported preliminary unaudited Q3 2026 revenue of approximately $4.3–4.4M (vs $3.4M a year ago), driven by ~$3.1M in teleradiology, $1.0M in AI/software (largely from consolidation of Vaso Health IT) and ~$0.3M in imaging/OEM sales; the company also announced a distribution deal in Italy for its Bone AI and Nanox.ARC X was named a TIME Best Invention of 2026. Management said cash, cash equivalents and deposits were about $26M as of Sept. 30 (down from $60M at year-end 2025), are not sufficient to fund operations for at least one year under current plans, and therefore raise substantial doubt about the company's ability to continue as a going concern without additional financing.

RMCF schedules fiscal Q2 2027 results call for Oct 19; no Q&A

Rocky Mountain Chocolate Factory (RMCF) will release its fiscal second-quarter 2027 results in a press release and host a management-only conference call on Monday, October 19, 2026 at 5:00 p.m. ET; the call will be webcast live and a replay will be posted on the company’s investor relations site. There will be no question-and-answer session on the call.

ADVASA (ADBT) board adopts dividend policy targeting 50% annual payout starting FY2027

ADVASA (ADBT) said its Board adopted a dividend policy targeting an annual cash dividend payout ratio of 50% of GAAP net income attributable to common stockholders, beginning with the fiscal year ending March 31, 2027. No dividend has been declared, no per-share amount or dates were set, and any future dividend remains discretionary and subject to legal, contractual and liquidity constraints.

Gauzy Announces $7 Million Private Placement Led by Management to Fund Court-Approved Settlement

OFS Credit (OCCI) declares $0.05 monthly distributions; DRIP at 5% discount

OFS Credit (OCCI) said its board declared monthly cash distributions of $0.05 per common share for each month of the quarter ending Jan 31, 2027, with record dates on Nov 16, Dec 15 and Jan 15 and payment dates on Nov 30, Dec 31 and Jan 29. Shareholders can reinvest via the DRIP at a 5% discount (shares issued at 95% of market on the payment date); the company did not provide NAV, coverage or longer-term guidance and the declaration covers only that single quarter.

Tigo Energy hit with securities class action after guidance cut; lead-plaintiff deadline Nov 23, 2026

Kaplan Fox filed a securities class action on behalf of investors who bought Tigo Energy (TYGO) between Feb 24 and Aug 4, 2026, alleging the company misled the market about the EG4 partnership and its revenue ramp; the complaint points to an Aug 4 guidance cut that lowered FY2026 revenue guidance from $130–$135M to $100–$110M and triggered an ≈37% share drop on Aug 5. Investors wishing to seek a lead-plaintiff role must move the court by Nov 23, 2026.

Nasdaq posts worst weekly drop in months as Dow edges up

The Nasdaq fell 3.64% on the week — its worst weekly stretch in months — while the S&P 500 dropped 1.43% and the Russell 2000 slid 2.43%, even as the Dow eked out a 0.93% weekly gain. Volatility rose (VIX 17.02, VXN 22.89), highlighting a split market between mega-cap tech weakness and broader resilience; the note also flags company-specific news including CLPS reporting FY2026 revenue up 4.7% to $172.2M with strong growth outside mainland China.

S-3 to Register 13.10M WORX Shares for Resale (mostly warrant shares)

SCWORX CORP. filed SEC Form S-3. The shares are held by investors and warrant holders from prior note and placement financings (July, Nov, Jan, Inducement and September financings); the company will not receive proceeds from selling stockholders' resales but would receive cash if warrants are exercised. If all warrants were exercised as modeled in the filing, outstanding shares would increase to 13,841,352; many warrants (except the September Warrants) include exercise-price adjustment provisions that can change actual dilution and shares issued.

Kaplan Fox files class action vs Innventure over alleged false DarkNX deal; lead-plaintiff deadline Oct 27, 2026

Kaplan Fox filed a class action on behalf of investors who bought Innventure (NASDAQ: INV) between Nov 17, 2025 and Aug 13, 2026, alleging the company misled investors about a purported Accelsius/DarkNX deployment and overstated 2026 revenue and cash flow targets; Innventure disclosed on Aug 13 that the DarkNX deployment site was no longer available and removed the project from bookings. Innventure’s stock dropped ~55% to $1.62 on Aug 14 after the disclosure, and Kaplan Fox is urging eligible investors to move to be lead plaintiff by Oct 27, 2026.

FatPipe (FATN) schedules Nov 4 webinar to present Q2 FY2027 results

FatPipe (NASDAQ: FATN) will host a 30-minute investor webinar on November 4, 2026 (4:30–5:00 PM ET) to present fiscal Q2 2027 financial results; senior management will review the quarter and provide business updates followed by a brief Q&A. Registration and access details are available via the company's investor relations channels.

Class action filed vs Tigo Energy after Aug 4 guidance cut; stock plunged ~37% (TYGO)

Kaplan Fox filed a securities class action against Tigo Energy (TYGO) alleging the company misled investors about the EG4 partnership and 2026 revenue expectations for purchases between Feb 24 and Aug 4, 2026. The complaint points to Tigo’s Aug 4, 2026 downward revision of FY2026 guidance from $130–135M to $100–110M as the corrective disclosure (the stock fell ~37% to $1.29 on Aug 5); investors have until Nov 23, 2026 to move for lead-plaintiff status.

Moleculin (MBRX) files 1-for-20 reverse stock split effective Oct 20, 2026

Moleculin (MBRX) filed to effect a 1-for-20 reverse stock split effective 12:01 AM ET on Oct 20, 2026, consolidating roughly 20.9M shares into ~1.05M shares; post-split shares will trade on Nasdaq under the same ticker with a new CUSIP and fractional shares will be paid out in cash. The company also disclosed it will require significant additional financing and currently has no commitments, a material funding risk for its ongoing clinical programs.

Class action filed against Endava over accounting; lead‑plaintiff deadline Nov 30, 2026

A securities class action was filed against Endava (DAVA) alleging the company misled investors about its accounting treatment of certain customer and supplier agreements for transactions between Sept 4, 2025 and Sept 21, 2026. The suit follows Endava's Sept 21, 2026 disclosure that CFO Mark Thurston was placed on administrative leave amid an internal accounting investigation, which preceded a >24% drop in ADS price on Sept 22; lead‑plaintiff deadline is Nov 30, 2026.

Insiders Buying in Defense/NatSec Tech — edgeTI Chair & CEO, Honeywell and Karman Make Market Purchases

Insiders across five defense and national-security tech companies reported open-market purchases since early September, notably Edge Total Intelligence’s chair (170k shares) and CEO (150k shares), a Honeywell Aerospace director who bought $998.4k of stock, and three Karman directors who bought roughly $1.04M combined. Insider buys are a visible alignment signal because they cost personal capital, but sizes vary by company and do not guarantee future performance or signal new contracts or earnings catalysts. Timing: Same-day dilution is possible only if the company starts sales under the facility, and the press release does not say when that could happen.

Insiders Buying in Defense/NatSec Tech — edgeTI Chair & CEO, Honeywell and Karman Make Market Purchases

Insiders across five defense and national-security tech companies reported open-market purchases since early September, notably Edge Total Intelligence’s chair (170k shares) and CEO (150k shares), a Honeywell Aerospace director who bought $998.4k of stock, and three Karman directors who bought roughly $1.04M combined. Insider buys are a visible alignment signal because they cost personal capital, but sizes vary by company and do not guarantee future performance or signal new contracts or earnings catalysts. Timing: Same-day dilution is possible only if the company starts sales under the facility, and the press release does not say when that could happen.

REVB to implement 1-for-7 reverse stock split effective Oct 20 to regain Nasdaq compliance

Revelation Biosciences (REVB) will implement a 1-for-7 reverse stock split effective the morning of Oct 20, 2026 to increase its per-share price and regain compliance with The Nasdaq Capital Market minimum bid requirement; shares will continue trading under the symbol REVB post-split. Warrants, RSUs and options will be proportionally adjusted, fractional shares will be rounded up to whole shares, registered holders need take no action, and broker-held positions will be adjusted per each broker's process.

SANGRIX Announces November 2026 Delivery Schedule for 128-GPU NVIDIA Blackwell B300 Project in Malaysia

Child shows early improvement after compassionate-use intranasal NEO100; NeOnc names Abu Dhabi banking exec to board

NeOnc reported a critically ill three-year-old with an aggressive brain tumor treated under compassionate-use intranasal NEO100 is breathing without ventilator support and beginning to move his legs. The company notes this single uncontrolled case was administered outside its pediatric trial and frames the update alongside regulatory and corporate milestones — a 24‑patient Phase 2a topline for NEO100 (6‑month PFS 48.9%, median OS 26.09 months), Abu Dhabi IND pathway progress and a new board appointment — plus a $15M registered direct raise and an upcoming Nov. 17 FDA End-of-Phase‑1 meeting for NEO212.

Fabric.AI to Join Nasdaq MarketSite Live AMA on AI Bottlenecks, Spotlighting Neural I/o Partnership

Fabric.AI (FABC) will participate in a live YouTube "Ask Me Anything" panel at Nasdaq MarketSite on Oct. 20, featuring Senior Strategic Advisor James Altucher alongside Kopin CEO Michael Murray and AI expert Cortney Harding. The discussion will focus on AI infrastructure constraints (data movement, energy, networking) and Fabric.AI’s jointly developed Neural I/o MicroLED optical interconnect technology with Kopin, aimed at easing data-movement bottlenecks; no new technical demos, commercial milestones or timelines were announced.

DETX names ex‑TSA exec Steve Karoly to board; CEO Bill Frain to depart end‑Oct

Liberty Defense (DETX) appointed Steve Karoly to its board effective immediately, replacing outgoing CEO Bill Frain who will leave the company at the end of October. Karoly is a 30‑year security and defense executive (currently EVP at K2 Security Screening Group) with prior TSA, CBP and DHS roles — including oversight of a $1B TSA budget and leading TSA innovation — experience that is directly relevant to federal procurement and transportation‑security deployments of Liberty’s HEXWAVE and other detection products; the release gives no CEO succession details or immediate contract/news implications.

Propanc says preclinical PRP remodels chemo‑resistant pancreatic cells, supports Phase 1b in Q1 2027

Propanc (PPCB) released preclinical data showing its lead proenzyme formulation PRP reprograms chemotherapy‑resistant pancreatic cancer cells and that PRP pre‑treatment increased subsequent sensitivity to chemotherapy, results the company says support a planned First‑In‑Human Phase 1b study in Q1 2027. In vitro models reported PRP cut proliferation ~50% (54% in resistant cells), reduced clonogenic survival, migration and invasion, reversed EMT markers (E‑cadherin up, vimentin/snail down) and showed stronger effects when combined with a TGF‑β inhibitor, though responses varied by model and no in vivo or clinical efficacy data were presented.

CLPS Incorporation Reports Financial Results for the Second Half and Full Year of Fiscal 2026

ATNM-400 shows broad preclinical activity in NSCLC, colorectal and ovarian models; data to be presented at EANM

Actinium (ATNM) will present preclinical EANM 2026 data showing its Actinium-225 radioconjugate ATNM-400 produced antitumor activity across KRAS- and ALK-driven NSCLC (including resistant models), improved responses in colorectal xenografts when combined with bevacizumab+oxaliplatin, and durable single-agent activity in ovarian models including bevacizumab-refractory tumors. These are preclinical xenograft results that the company says support a mutation-agnostic, pan‑tumor development strategy and both monotherapy and combination approaches, but no clinical efficacy or safety data were reported yet.

TRUG says acquisition of Polymath/Polymesh positions it in regulated tokenization and digital securities infrastructure

TruGolf (TRUG) says it closed the acquisition of Polymath Research Inc. and Polymesh, giving the company ownership of a Layer‑1 blockchain and infrastructure for regulated tokenization of securities and real‑world assets. TruGolf plans to pilot the infrastructure inside its franchise network and highlights Polymath’s exploration of a tokenized film investment platform, signaling expansion beyond golf into broader digital‑securities use cases, though financial terms and commercialization timing were not disclosed.

Audio feature spotlights AZIO's 'AI factory' power-to-compute strategy

An audio feature titled "Contracted Capacity Becomes Key Metric..." highlighted AZIO AI Holdings (AZIO), describing 'AI factories' that convert electricity into usable compute and emphasizing AZIO's integrated model of behind‑the‑meter power, data‑center hosting, connectivity and enterprise GPU access. The segment is promotional and raises investor visibility but provides no new contracts, financial metrics, timelines, or material operational disclosures.

Aprea (APRE) to host pre‑ESMO virtual panel on WEE1 inhibition; APR‑1051 in Phase 1

Aprea will host a virtual panel titled “The State of WEE1 Inhibition in Precision Oncology” on Oct 20 ahead of ESMO to discuss WEE1 biology, class selectivity challenges and near‑term watch points. The company noted its lead program APR‑1051 is an oral WEE1 inhibitor currently being evaluated in the ongoing Phase 1 ACESOT‑1051 study in biomarker‑defined advanced solid tumors; no new clinical data were released.

Vertical Aerospace signs long-term suppliers: ANH for seats, Northrop Grumman LITEF for inertial nav on Valo eVTOL

EVTL filed SEC Form 6-K. The filing states ANH holds EASA Design and Production Organisation Approvals and will use its 30G energy-absorption seat technology, NG LITEF's LCR-110 meets applicable EASA/FAA technical standards, and Vertical reiterates it has about 1,500 Valo pre-orders, but discloses no financial terms, delivery schedules, or pricing.

BMRA Q1 FY2027: inFoods Medicare claims paid at $300; revenue $1.3M, loss $1.2M, cash $2.7M

Biomerica (NASDAQ: BMRA) reported Q1 FY2027: net sales ~$1.3M, gross profit ~$103k (8% margin), operating and net loss of approximately $1.2M, and cash of ~$2.7M after a $2.23M private placement. Commercially, inFoods® IBS is gaining Medicare traction — 100% of initial valid Medicare claims processed as of Oct 15 were paid at the full CMS rate of $300 and Medicare-related test orders rose 120% in September vs August — and the company engaged B. Riley to evaluate strategic opportunities while advancing CDM work with potential initial fees >$1.75M.

SCNI closes $4.0M private placement, issues Series A‑1 warrants; existing warrants exercised at $1.20

Scinai (SCNI) closed a private placement of 2,458,334 ADSs (or pre‑funded warrants in lieu) and issued Series A‑1 warrants to purchase up to 3,687,501 ADSs; it also closed the immediate exercise of Existing Warrants for up to 879,194 ADSs at a reduced $1.20 per ADS and issued an additional 1,318,791 Series A‑1 warrants. Aggregate gross proceeds were approximately $4.0 million before fees, the company received proceeds and the transactions are closed, so dilution from the issued ADSs/pre‑funded warrants is immediate; future dilution from the new Series A‑1 warrants would occur if/when exercised. Each ADS represents 40,000 ordinary shares; the company said it will file a registration statement to register resale of the private placement ADSs, ADSs issuable upon exercise of pre‑funded warrants and new warrants, and A.G.P. acted as sole placement agent. Timing: Shares were issued at closing; initial share dilution has already occurred.

Curis prices ~$8.5M private placement of 16.7M units with $0.60 warrants

Curis announced a private placement of 16,666,680 common shares (or pre-funded warrants in lieu) plus common warrants to purchase up to 16,666,680 shares at a combined effective price of $0.51 per unit, expected to raise approximately $8.5M before fees. The common warrants carry a $0.60 exercise price, are exercisable six months after issuance (expire 5.5 years after issuance), and pre-funded warrants have a $0.01 exercise price and are exercisable immediately; the offering is expected to close on or about October 19, 2026. The company also agreed to amend existing warrants (1,126,676 January-2026 warrants and 3,733,334 August-2026 warrants) to a reduced $0.60 exercise price, creating additional potential future dilution of up to 4,860,010 shares. Timing: The press release does not indicate dilution today. Earliest dilution: Oct 19, 2026 settlement. Earliest dilution: Oct 19, 2026 settlement.

Azitra (AZTR) to implement 1-for-10 reverse stock split effective Oct 26, 2026

Azitra (AZTR) will implement a 1-for-10 reverse stock split effective 12:01 AM ET on Oct 26, 2026, with shares trading on a split-adjusted basis on the NYSE American under AZTR when the market opens that day. The split reduces outstanding shares from ~60.6M to ~6.06M, will proportionally adjust equity awards and warrants, and fractional shares will be paid out in cash (without interest) based on the five trading-day pre-split average closing price.

La Rosa Holdings Corp. to Change Its Name to Stratum Holdings Corp., Reflecting Its Transformation into an AI Infrastructure Company

OMEX S-4 Effective; 1-for-25 Reverse Split Oct 29; Merger Vote Dec 2

Odyssey Marine (OMEX) said the SEC declared its Form S-4 effective for the proposed merger with American Ocean Minerals and set a special stockholder vote for December 2, 2026; the definitive proxy/prospectus will be mailed beginning on or about October 21. Odyssey will effect a 1-for-25 reverse stock split effective October 29, 2026 (shares to trade on a split-adjusted basis that day), which will reduce outstanding shares from ~58.6M to ~2.3M and is a condition to certain investors providing post-merger financing; the merger remains subject to stockholder approval and other closing conditions. Timing: Dilution depends on stockholder approval first, and the press release does not say when that will happen.